For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both.Featuring daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, the research service can help you become a smarter, more self-assured investor.It also includes access to the Zacks Style Scores. What are the Zacks Style Scores? The Zacks Style S ...

Company Overview - Elanco Animal Health Incorporated (NYSE:ELAN) specializes in veterinary medicine, providing products for the protection and treatment of pets and farm animals, including parasiticides, vaccines, therapeutics, and medicated feed additives [3]. Stock Performance - The stock has shown a remarkable performance, increasing by 137% over the past 12 months and nearly 17% since the beginning of 2026 [1]. - Following a strong quarterly report, Elanco's stock rose by 6.6% [1]. Financial Highlights - The company reported a 12% revenue growth, attributed to strong performance in both pet health and farm animal segments [1]. - Elanco achieved a 2-cent earnings beat, reporting earnings of 11 cents per share [1]. - Management provided a solid full-year forecast, indicating confidence in continued growth [1][2]. Management and Strategy - The management has successfully turned the company around, demonstrating effective strategies that have impressed analysts [2].

Group 1 - Elanco Animal Health Incorporated (NYSE:ELAN) has successfully turned around its operations, leading to a significant stock price increase of over 83% since January 21 [1] - The company specializes in products for the protection and treatment of pets and farm animals, including parasiticides, vaccines, therapeutics, and medicated feed additives [1] - Despite the positive turnaround, there are opinions suggesting that other stocks, such as Chewy, may present better investment opportunities within the same sector [1] Group 2 - There is a belief that certain AI stocks may offer greater upside potential and carry less downside risk compared to ELAN [2]

Core Insights - Zoetis Inc. is a leading company in the animal health industry, offering a variety of products and services for both pets and livestock, with a focus on innovative solutions in parasiticides, diagnostics, and dermatology [1] Financial Performance - In Q3 2025, Zoetis reported an adjusted earnings per share (EPS) of $1.70, exceeding the consensus estimate of $1.62 [2][6] - The adjusted net income for the company reached $754 million, marking a 5% increase on a reported basis and a 9% rise on an organic operational basis [3] - Total sales for Zoetis amounted to $2.4 billion, reflecting a 1% year-over-year increase, although slightly below the expected $2.41 billion [3] Market Position and Challenges - Despite facing challenges with monoclonal antibody products for osteoarthritis pain, such as Librela and Solensia, which saw a decline in sales, Zoetis continues to maintain a strong market presence [4][6] - Sales of livestock products decreased by 9% due to the divestiture of the medicated feed additive product portfolio [4] - The stock price for Zoetis is currently at $126.06, down approximately 12.67% from its previous high, with a market capitalization of around $55.87 billion [5]

Group 1: Zacks Premium Overview - Zacks Premium offers various tools for investors to enhance their stock market engagement, including daily updates on Zacks Rank and Industry Rank, access to the Zacks 1 Rank List, Equity Research reports, and Premium stock screens [1] - The service aims to help investors become more informed and confident in their investment decisions [1] Group 2: Zacks Style Scores - Zacks Style Scores are indicators designed to assist investors in selecting stocks with the potential to outperform the market within a 30-day timeframe, rated from A to F based on value, growth, and momentum characteristics [2] - The Style Scores are categorized into four types: Value Score, Growth Score, Momentum Score, and VGM Score, each focusing on different investment strategies [3][4][5][6] Group 3: Zacks Rank and Performance - The Zacks Rank is a proprietary stock-rating model that leverages earnings estimate revisions to guide investors in building successful portfolios [7] - Stocks rated 1 (Strong Buy) have historically produced an average annual return of +25.41% since 1988, significantly outperforming the S&P 500 [8] - There are over 800 stocks rated 1 and 2, which can be overwhelming for investors, highlighting the importance of Style Scores in stock selection [9] Group 4: Stock Highlight - Zoetis Inc. (ZTS) - Zoetis Inc., based in Parsippany, NJ, specializes in animal health products and was spun off from Pfizer, trading on the NYSE since February 1, 2013 [12] - The company serves both livestock and companion animals across various product categories, including parasiticides, vaccines, and anti-infectives [12] - Zoetis holds a 3 (Hold) rating on the Zacks Rank with a VGM Score of B, and its shares have increased by 0.8% over the past four weeks [13] - The company has seen upward revisions in earnings estimates, with the Zacks Consensus Estimate rising by $0.18 to $6.26 per share for fiscal 2025, and it boasts an average earnings surprise of 5.2% [13][14]

Core Insights - Zacks Premium provides various tools for investors to enhance their stock market engagement and confidence [1] - The Zacks Style Scores are designed to help investors select stocks with the highest potential to outperform the market in the short term [3] Zacks Style Scores Overview - The Zacks Style Scores categorize stocks into four types: Value Score, Growth Score, Momentum Score, and VGM Score, each focusing on different investment strategies [4][5][6][7] - Value Score identifies undervalued stocks using financial ratios [4] - Growth Score assesses a company's financial health and future growth potential [5] - Momentum Score capitalizes on existing price trends to identify favorable investment opportunities [6] - VGM Score combines all three styles to highlight stocks with the best overall characteristics [7] Zacks Rank and Performance - The Zacks Rank is a proprietary model that utilizes earnings estimate revisions to guide investors in stock selection [8] - Stocks rated 1 (Strong Buy) have historically achieved an average annual return of +25.41% since 1988, significantly outperforming the S&P 500 [9] - Investors are encouraged to focus on stocks with a Zacks Rank of 1 or 2 and Style Scores of A or B for optimal returns [10] Company Spotlight: Zoetis Inc. - Zoetis Inc. specializes in animal health products and was established after Pfizer spun off its animal health division [12] - The company operates in seven major product categories and serves both livestock and companion animals [12] - Currently, Zoetis holds a Zacks Rank of 3 (Hold) with a VGM Score of B, indicating moderate potential [13] - The stock has shown a 7.4% increase over the past four weeks, with positive earnings estimate revisions for fiscal 2025 [13] - Given its solid rankings and momentum, Zoetis is recommended for investors' consideration [14]